Sol-Gel's acne drug could emerge as a significant topical treatment - Jefferies

SOL-GEL TECHNOLOGIES

31/12/2019 11:40

** Jefferies says Sol-Gel Technologies's  SLGL.O  acne
treatment could emerge as a significant topical treatment based
on "best in class" characteristics vs leading drugs Aczone and
Epiduo Forte
    ** SLGL surged 60% on Monday after company said its lead
drug candidate, Twyneo, met main goal of reducing acne marks in
two late-stage studies  urn:newsml:reuters.com:*:nL4N2941UL
    ** Brokerage raises PT to $24 from $14, which implies an
upside of 64.4% to stock's last close; median PT is $21 
    ** Expects Twyneo and co's skin disease drug, Epsolay, to
bring in combined peak sales of $300 mln
    ** Twyneo is the first of its kind to combine benzoyl
peroxide and tretinoin; Individually, the two chemical
components are widely used to treat acne
    ** Current avg. rating on stock is "buy"
    ** Stock has more than doubled in value YTD

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6749 7786;))